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This study " 'as designed to determine the fate 01" the nonsteroid antiand rogen nut amide in 
men following a single 6-hr topical appli('ation of 5 mg I·C-labeled drug d issol\'ed in SO q;: 
ethanol /SO(r,. propylene glycol. Analys is of 0- 120 hr urine !=ihows at least 16r ; of t.he applied 
f1utamide is absorbed. Fifty-six per('ent of the dose is recovered from the s it e of application 
with cotton swabs moistened with 50 1:; ethanol /50 r : propylene glycol. Flut amide pl asma 
levels peak in 4 to 6 hr at about 1.:1 ng/ ml and then decline rapidly to about 0.08 ng/ ml 24 hr 
after application . Onl~' l ~ ('i- of plasma I·e is as~ociated with flutamide 6 hr after drug 
application. There a re at least 10 plasma metabolites. of which 6 have been tenlati\'ely 
identified . These a re a.a.a-l r if1uoro~"\ · -a mino - m-acetotoluidide (A); 0',a.a-t rifluoro-4 '-
amin o-2- methy l-m-lBclotoluidide (8); O',O'.O'·t rif1uoro~.,I' -n it ro·m-acetotoluidide (Cl: a.a.O'-
t r if1uoro-2- meth.\"I-.,I ' -nit ro-m-Iactotoluidide ( 0 1: a.lY.lY-t rif1uoro-"\ '-a min o-2- methyl-m-propio-
notoluidide (EL and H.n.('t'· trifluoro-6-ni tro·m-lOluidine (FI. 
lD) is the major plasma metabolite. and its concent rat ion exceeds l1utamide 's between B 
and :24 hr after drug:. All the plasma metabol ites are found in O- l4 hr urine in minor amounts. 
An additional metabolite. H,C\.n-\rinuo r()-am inn-;)- nitm-p-(T€,~()\ tl; l. a{,('oun\~ for 27 , of 
urine I·e. 
Flut amide is a potent. nonsteroid antiandrogen 
in animals l1.2J that i~ being tested clinically for 
treatment of prostatic carci noma [31. Its fate in 
men after a single oral 20D-mg dose has been 
studied \41. Because flUlamide is actiyp topicall~' 
]5). and is pOlentially useful for treatment of acne 
and hirsuti:-.m. we studied its fate in 5 men afte r 
topical appii<:ation of:) mg of I·e·labeled drug. 
~:lATERIAL~ A;'\D ~'lETH ODt-; 
Radioche mical assa'y~ a nd isolation and quantitalion 
of metabolites ha \'e heen d{'!';cribe-d 141. 
Preparation of He-Labeled Flutamid e 
Labeled drug' was prepared from II·C ICf 3· m -
aminobenzolril1uoride (Mallincrodt. St. Loui!'. Mo. ) by 
reA ction with isobuty r ic- anh~tdride to yield an anilide 
which waR then ~electively nitrated to y ield jUC ICF,-
f1utamide (!5P act appro~imately ~O .u Ci (n1.p: 1. C hemical 
purity was > 99Cl( and radiochemical purity > 98("j by 
TLC in solvent ~y~tems B. r. D. and E (see sect ion On 
Chromatowaphy for (·nmposition ). 
J)ru# Administrat ion and Sample Collection 
The experiment wa:o performed afler informed consent 
was obtained from each of the su bject s. Two hundred 
Manusc ript received October 9. 1975: in revised form 
Janua r~' 15, 1976: accepted for public81ion January 16_ 
1976. 
Reprint reque!'ts H): Dr. B. Katchen. Departmem of 
Biochemi!': try_ Biological Resea rch Divi~ i on. Sl:hering 
Corporation. Bloomfield. New .Jersey 07003. 
Abbreviat ions: 
NMR: nuclear magnetic resonan ce 
SE: s tanda rd error 
TLC : thin · layer ch romatography 
microlit ers of 50 <"; propylene ~!ycol /:io r; ethanol contain· 
ing 5. 16 mg 11 'e Jlluwmide ( ~9.77 IJ.Ci / mg) wa!' applied to 
a I OO-cm 1 (51 .6 IJ.~/cm 7) a rea on t he uppe r back of each of 
5 healthy male volunteers. A hemispheri(·a l. perforated 
plastic {' UP was taped oYer the treated areIJ and removed 
after 6 hr . The treated area was then swabbed wit h conon 
moistened with 50 r;. propylene glycol/50S ethyl alcohol. 
"c in the cotton sWBb~ was ext ract ed with ethyl alt'uhol 
and. aflE'r dryin~. an aliquot o f each swab \ .... as hyd rolyzed 
in 6 N HCI and the hydrolY!>B te was: assayed for 14C . 
Ten milliliters of blood (in heparinized tubesl were 
co llected immediately before (zero time) and 1. 2. 4,6.8. 
IZ. 16, 2~. -l8. and 7'2 hI' after drug . T otal u r ine samples 
were ('ollected commencin?: 24 hr prior to and continuing 
up to 120 hr afler drug-. 
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FIG. 1. Excretion of "c in urine by men following 8 
single topical 5·mg do!\e of [He Jf1ulamide. Values are 
average of 5 subject!> ::t. SE. 
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380 K ATCHf:N. DANCIK . AND MILLlN(;TON 
Chromatopraph,' 
All Chrom8{()~ra ph ic separations were carried out on 
E. Merck 250-1-1 Silica gel GF plates (Brinkma nn In-
struments. Inc .. West bur\", N. Y.) with solveOi svSl ems 
of the rollowi n ~ com posiiion tv/v): A. CHCIl: t'lh'yl ace· 
tate, 3: 1: B. loluene:tetrahydrofuran. 9:1: C. toluene: 
oo, L--}.--~~r-,~ -~~~~.-•• ~,-.~ ~~.-~~,-,~~~" 
....... 
FIG. 2 . Plasma rad ioactivity in men followi n~ a si ngle 
topical 5-mg dose of tHe ]Outamide. 
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FIG . . 1. Flutsmide metahnlism in men . 
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FIG. 3. Plasma metabolites in men following a single topica l 5- mg of I He Iflulamide. Values a re average of 5 sub· 
jects ± S E. 
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FI (; _ .1. Ur ine metahn]ite~ in men fol ill wing a sinJ! le top ical f)-mg d ose of /, tCjflutamide_ Ethy l acetate extract of 
GI usu lase- treat ed urine W8!oi ('ochro ma tographed wit h referl'nct' !Otandard!' in !'~{stem A. Values a re average of;) subjects, 
, SE. 
ethyl aCeta te. 5: I: D. CH t C'l1: E, C Hf'I ,: diethyi ethe r, 
8,Z, 
Identificafion and Quant ito/inn of M etabolites 
All metaholite!' were pre\·iou:;.]y iRoialed a nd ide nT ified 
in p ilot animal ex perimenl~ hy com par i!'on with authen· 
t ie ~ t a nd/lrd ~ via mass spcrtromet ry. (G) \\-'as also idenr i-
fied by its :-':MR RpeCtrum" , Detailed proo/!:. ofRt ru('ture 
will be presented (.J . M('Glol1l':' ll . -J . M ortoil , a nd E. Gn ld. 
unpublished data). 
Fl utamide and it!' metaboli tes were quantit a ted as 
foHnw!;: One ml of p\a~ma or UTine from earh sUhjccl was 
buffered at p H ;' .0 a nd incuhated 16 hr at :'{j°C with 0.1 
ml (If a mixture (If (:t-~Iu('u rnnida!<.t' and ~ulfata"t' (Glusu-
lase. Endo LaborafOr ie;:-., Garden Ci ty. N. Y.I. The 
metabolites were extracted with 10.01111 ofe-thyl aceUli e. 
and an 8.0-m l aliquot of the elh .vl acetate ext ract was 
evaporated under a ~;tream of dr." nitrogen to about 0_1 
ml. wh ich was then spoiled (In a ~ilira g-el th i n - Ia~ler 
plate. The luhe cont aining the re~i dlle was rin sed with 2 
O.Ofl-ml po r' ion~ of methanol which were spoued on top 
of the fi r!'! ~pf)t . Appropr ia te ('a rr ier~ were r-och romato-
l!Taphed with Ih l? unknuwn in ~u\ven\ l'oys\ em A. After 
d rying: . the SpOl!' wert' sn uped from the plate int o 
counting vial s for assay of the ir H(' C(lntent. Sample!' 
contain inf;! 10 cpm or less a bove hackground (equivale nt 
to pl asma level s of abou t 0.1 n ~/rnl or less) we re coun ted 
fo r 120 min . S uffi cient count s were collected to dis t in -
guish sa mple from backg-round a t p < 0,0.5. 
.. Copies of the N MR and mass s pectra a re available on 
request from the authors. 
HESl'LTS 
Excretion Pattern 
F igure I shows that 16, 1 C; (SE ~ 1.9"; \ of the 
applied flu tamide is excreted in urine. About 9/ r , 
o f the exc retion occurs in the first 24 hr after d rug 
application and then rapidly declines. 
Recovery of " C from Site of Application 
Cotton swabs of the site of application 6 hr afte r 
drug- a ppl ie8 tion conta in 5W'( (S E =- 4.7 f( ) of the 
applied dose. Re<'o\'er~' of l4C fro m u rine and the 
si te of application account s for 72" (SE ~ 5,:1 c:t ) of 
the dos€'. 
Plasma M etabolite.< 
Total pla:;; ma 14e peaks 8 hr after drug a t 10.2 ng 
equi\'alents flutamide/ ml and then declines mul-
tiexponent ia lly (Fig, 2), F lutamide le\'el5 peak 
aboul 6 hr after drug a t I. :Jl ng/ ml a nd a lso 
disappear multiexponentially, ID \. Ihe ,,-O H de-
ri\'ati\'e of flutamide. is the major plasma metabo-
lite after 6 hr a nd disa ppears with about a 6- hr half 
life (Fig, 2\, 
At leas t 5 othe r eorn pounds are in th e ex tracta-
ble fracti on (Fig, 3), but they account fo r no more 
than 30"( of total plasma I·e up to 8 hI after drug. 
(D) and flutamide account fo r about 70 q( of the 
identified compounds. 
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A possible metabolic scheme for flutamide IS 
shown in Fi:;ure 4. 
Urine Metabolites 
Following hydrolysis with Glusulase. 78 to 81 "1 
of the radioacti\' ity is extractable with ethyl ace-
Late. Thirty- five to forty-four percent is extrac ta ble 
before Glusulase hydrol~·s is . TLC of t he fra ction 
ext ractable after Glusulase hydrolysis shows about 
half of the I~C is present as polar met a bolites (R( < 
0.15). The compounds with R, > 0.15 a re present 
in sm all amounts. except for (GL which account s 
for ahout 30% of the extractable radioaCI ivity 
(F ig. 5), 
D1SCTSSSIOK 
Flutamide is rapidly and almost compl ete ly 
convert.ed to other compounds b~' men 1 hr afte r 
oral administration 14 J. The plasma concentration 
of (0 ) is about 10 times greater than the concent ra-
tion of f1utamide . This suggest s it is la rgel~' me-
tabol ized on its fi rst pass through the liver . In 
cont rast. 4 to 8 hr after topical ad minist ration, 
fluta rnide and (0 ) plasma concentrations a re 
rou~hlv equal. 
The :;arne metabolites are present in urine and 
plasma foIlO\ ... ·ing oral and topical doses, which 
suggests that topical administration affects only 
the rate at which flutarnide is metabolized. The 
metabolic scheme (Fig. 41 we ha ve proposed for 
f1utamide suggest.s that the isobu tyryl side chain is 
removed by stepwise oxidation ra ther th an hydrol-
ys is. On ce the side chain is remo\'ed. the resul t ing 
nitro aniline or phenylenediamine is hydroxylated 
to (0) and othe r unidentified compounds. 
Recovery of radioacti\'it~, from urine and the site 
of application accou m for 72 C'f- of the dose. How-
ever. stud ies in men following oral admin istra tiun 
of 200 mg of llH Jflutam ide show the drug is 
complet ely absorbed and that gO; of the do~e is 
excreted in feces [4]. Assuming t he excretion 
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pattern is s imilar after topical administration, we 
would expect to find about 1.6 r;1 of t.he dose in 
feces. This mean s 17.7 l1 ( lG . I C7O( in urine -t 1. 6 (~ in 
fecesl of the applied Il utamide penetrated in 6 hr. 
P resumabl;v·. the remainder is at the site of a pplica-
tion. 
Meaningful co mparison of our findings wit h 
those of ot.her percutaneou~ ab~orption st udies in 
t.he literature is difficu lt becau~e of wide differ-
ences in the test sy~tem s that were employed . Onl~' 
one stud~1 [61 used 8 tes t system si mila r to Ou rs. Of 
21 organic chemi('als. cove ring a wide ran1!e of 
structures and solubilities, just one, djeth~I It ()lua m ­
id e. resembled ilutamide in rate and extent of 
percut aneo us penet rat ion . 
The au thors thank Dr. Eli Gold for l"' nlhe~is [I f the 
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